For the treatment of moderate to severe hidradenitis suppurativa (HS) in patients 12 years of age and older
At week 12, many moderate to severe adult HS patients treated with HUMIRA achieved clinically meaningful improvement, defined as Hidradenitis Suppurativa Clinical Response, or HiSCR, vs placebo.1,3
Numerical assessment of HiSCR in a theoretical patient from the PIONEER study2
Abscess and inflammatory nodule count was reduced from 20 to 10 in both cases. In the HiSCR nonresponder, however, abscesses increased to 8.